Capricor Faces Securities Class Action Over Deramiocel BLA Data-Plan Changes
Aug 1, 2026, 3:13 PM EDT4 sourcesAI-analyzed
Why it may matterVerify against the original reporting
Securities class actions can introduce material upside or downside depending on settlement costs, potential penalties, and regulatory trajectory. For a small-cap biotech like CAPR, such actions often create near-term stock weakness due to elevated risk and uncertainty, even if the case does not settle quickly. Past biotech actions show driven moves around filings, certification status, and any new, price-relevant disclosures.
AI summary
What happened, with direct paths to the underlying reporting
Schall, Brown & Schwartz LLP filed a securities class action against Capricor Therapeutics alleging misstatements about Deramiocel and its BLA data plan. The complaint claims Capricor altered its statistical analysis without FDA approval before resubmission, elevating regulatory risk and potential damages to investors. The development could trigger near-term volatility as the case progresses, with longer-term impact contingent on outcome and any settlements.
SBS files Capricor securities class action.
Alleges misstatements about Deramiocel and BLA data changes.
Class period Dec 17, 2025–Jul 26, 2026; lead plaintiff deadline Sept 28, 2026.
Impact on CAPR valuation depends on FDA outcome and legal costs.
How to read this signal
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.
Related signals
More source-backed signals connected by company or event
Capricor reported that the FDA extended the PDUFA target date for Deramiocel to November 22, 2026 after submitting a major amendment with 24-month HOPE-3 data aimed at a refined u…
Capricor Therapeutics surged in premarket trading after news the FDA is willing to review new data on its experimental Duchenne muscular dystrophy therapy. The regulatory openness…
Capricor reported that the FDA advisory committee found Deramiocel's evidence insufficient for Duchenne cardiomyopathy, a non-binding result that tempers near-term approval prospe…
Capricor Therapeutics faces a securities-law investigation by Johnson Fistel amid Reuters detailing FDA concerns over deramiocel data and trial design. The disclosure triggered a…
